JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The Inflammatory Characteristics of Symptomatic Glioma Associated With Poor Prognosis and Chemoresistance via Tumor Necrosis Factor Signaling Pathway

  • 0Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Korea.
Brain Tumor Research and Treatment +

|

November 14, 2024

|

November 14, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Symptomatic gliomas show increased inflammatory responses linked to poor prognosis and chemoresistance. Immediate treatment of incidental gliomas may improve patient outcomes compared to a wait-and-see approach.

Area Of Science

  • Neuro-oncology
  • Molecular Biology
  • Immunology

Background

  • Incidental gliomas represent a small percentage of gliomas, with ongoing debate regarding immediate treatment versus observation.
  • Limited molecular and immunological data exist to guide treatment decisions for incidental gliomas.

Purpose Of The Study

  • To compare molecular and immunological differences in the tumor microenvironment between incidental and symptomatic gliomas.
  • To investigate the role of specific molecular pathways, such as TNF signaling, in glioma prognosis and treatment response.

Main Methods

  • Retrospective analysis of total RNA sequencing (RNA-seq) and single-cell RNA sequencing (scRNA-seq) data.
  • Classification of glioma samples based on symptom data from The Cancer Genome Atlas (TCGA) and other public datasets.
  • Enrichment analysis, survival analysis, and identification of differentially expressed genes.

Main Results

  • Symptomatic gliomas exhibit distinct gene expression profiles compared to incidental gliomas, with 104 common upregulated genes in symptomatic cases associated with immunological pathways.
  • Single-cell RNA sequencing identified 11 cell types, highlighting the significant influence of tumor necrosis factor (TNF) signaling on myeloid cells.
  • TNF signaling was correlated with temozolomide resistance and a poorer prognosis in glioma patients.

Conclusions

  • Symptomatic glioma is associated with enhanced inflammatory responses, poorer prognosis, and chemoresistance.
  • The findings support the immediate treatment of incidental gliomas to potentially improve patient outcomes.
  • Molecular and immunological profiling provides critical insights for personalized glioma treatment strategies.

Keywords: